多西他赛联合顺铂诱导化疗治疗Ⅲ、Ⅳa期鼻咽癌的临床疗效  

Clinical Efficacy of Induction Chemotherapy with Docetaxel and Cisplatin for Ⅲ and Ⅳa Nasopharyngeal Carcinoma

作　　者：韦军[1] 

机构地区：[1]四川省自贡市第三人民医院,643020

出　　处：《实用癌症杂志》2015年第6期886-888,共3页The Practical Journal of Cancer

摘　　要：目的评价多西他赛联合顺铂诱导化疗治疗Ⅲ、Ⅳa期鼻咽癌(NPC)的临床疗效。方法将59例Ⅲ、Ⅳa期鼻咽癌患者随机分为2组,多西他赛联合顺铂(TP)组29例和顺铂联合氟尿嘧啶(PF)组30例。各组均接受3周期的诱导化疗。观察2组患者治疗期间的不良反应和耐受性,以及近期疗效。采用Kaplan-Meier分析,计算生存率。结果化疗结束后TP组有效率为89.6%,PF组有效率为86.7%。治疗结束后,平均随访时间29个月。TP组9例患者出现复发,其中2例局部复发,4例远处转移,3例转移且随后死亡。3年的整体和无进展生存率分别为94.9%和84.7%。PF组14例患者出现复发,其中6例局部复发,3例远处转移,5例转移,其中3例死亡。3年的整体和无进展生存率分别为83.6%和79.5%(P<0.05)。TP组和PF组3级以上急性毒性有差异(P<0.05)。结论多西他赛联合顺铂是一种可行且耐受的NPC治疗方法。Objective To evaluate the clinical efficacy of docetaxel plus cisplatin induction chemotherapy for Ⅲ,Ⅳa nasopharyngeal carcinoma( NPC). Methods 59 cases of stage Ⅲ and Ⅳa NPC were randomly divided into 2 groups,docetaxel plus cisplatin( TP) group( n = 29),cisplatin plus fluorouracil( PF) group( n = 30). Each group underwent 3 cycles of induction chemotherapy. Adverse reactions,tolerability,short-term efficacy of the 2 groups were observed. Kaplan-Meier analysis was used to calculate survival rate. Results Effective rate in the TP group after chemotherapy was 89. 6%,and that of PE group was86. 7%. After treatment,the mean follow-up time was 29 months. In the TP group,there had 9 cases of recurrence,including 2 cases of partial recurrence,4 cases of distant metastasis,3 cases of distant metastasis and follow-up post-death. 3-year overall and progression-free survival rates were 94. 9% and 84. 7%. In the PF group,there had 14 cases of recurrence,including 6 cases of partial recurrence,3 cases of distant metastasis,5 cases of metastasis,3 cases of death. 3-year overall and progression-free survival rates were 83. 6% and 79. 5%( P < 0. 05). TP group and PF group above stage Ⅲ acute toxicity incidence had significant difference( P < 0. 05). Conclusion Docetaxel plus cisplatin is a feasible and tolerable treatment for NPC.

关 键 词：诱导化疗 多西他赛 顺铂 局部晚期 鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤]